<DOC>
	<DOCNO>NCT00658515</DOCNO>
	<brief_summary>This study evaluate potential RO4607381 reduce cardiovascular morbidity mortality stable coronary heart disease patient recent Acute Coronary Syndrome ( ACS ) evaluate long term safety profile drug . Eligible patient stable condition randomize receive either RO4607381 600mg po placebo po , daily , together background standard medication ACS ( include aspirin , antihypertensives statin ) . The anticipated time study treatment 2+ year , target sample size 15,600 individual .</brief_summary>
	<brief_title>A Study RO4607381 Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Dalcetrapib</mesh_term>
	<criteria>adult patient , &gt; =45 year age ; recently hospitalize ACS ; clinically stable ; receive evidencebased medical dietary management dyslipidemia . uncontrolled diabetes ; clinically unstable ; severe anemia ; uncontrolled hypertension ; concomitant treatment drug raise HDLC ( eg niacin , fibrates ) .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>